Chronic itch, epidermal barrier disruption, and type 2 immune activity make atopic dermatitis a challenging area. It is within preclinical drug research and reliable in vitro models. It remains essential for compound profiling and pathway investigation. Keratinocyte assays, cytokine stimulation systems, and skin inflammation platforms help scientists examine immune signalling under controlled laboratory conditions.Cellomatics Biosciences provides tailored assay solutions which support candidate screening for inflammatory skin disorders across biotech and pharmaceutical pipelines.